Our top pick for
Trxade Group, Inc is a pharmaceutical retailers business based in the US. Trxade Group shares (MEDS) are listed on the NASDAQ and all prices are listed in US Dollars. Trxade Group employs 29 staff and has a trailing 12-month revenue of around USD$16.8 million.
|52-week range||USD$4.01 - USD$8.25|
|50-day moving average||USD$6.3427|
|200-day moving average||USD$5.7024|
|Wall St. target price||USD$10.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.0485|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Trxade Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Trxade Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Trxade Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3256x. In other words, Trxade Group shares trade at around 3256x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Trxade Group's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$515,212.
The EBITDA is a measure of a Trxade Group's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$16.8 million|
|Gross profit TTM||USD$4.9 million|
|Return on assets TTM||-1.34%|
|Return on equity TTM||-9.77%|
|Market capitalisation||USD$52 million|
TTM: trailing 12 months
There are currently 18,746 Trxade Group shares held short by investors – that's known as Trxade Group's "short interest". This figure is 78% down from 85,044 last month.
There are a few different ways that this level of interest in shorting Trxade Group shares can be evaluated.
Trxade Group's "short interest ratio" (SIR) is the quantity of Trxade Group shares currently shorted divided by the average quantity of Trxade Group shares traded daily (recently around 93730). Trxade Group's SIR currently stands at 0.2. In other words for every 100,000 Trxade Group shares traded daily on the market, roughly 200 shares are currently held short.
However Trxade Group's short interest can also be evaluated against the total number of Trxade Group shares, or, against the total number of tradable Trxade Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Trxade Group's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Trxade Group shares in existence, roughly 0 shares are currently held short) or 0.005% of the tradable shares (for every 100,000 tradable Trxade Group shares, roughly 5 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Trxade Group.
Find out more about how you can short Trxade Group stock.
We're not expecting Trxade Group to pay a dividend over the next 12 months.
Trxade Group's shares were split on a 25:1 basis on 11 August 2008. So if you had owned 1 share the day before before the split, the next day you'd have owned 25 shares. This wouldn't directly have changed the overall worth of your Trxade Group shares – just the quantity. However, indirectly, the new 96% lower share price could have impacted the market appetite for Trxade Group shares which in turn could have impacted Trxade Group's share price.
Over the last 12 months, Trxade Group's shares have ranged in value from as little as $4.01 up to $8.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trxade Group's is 1.3346. This would suggest that Trxade Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Trxade Group, Inc., together with its subsidiaries, owns and operates a business-to-business (B2B) web-based marketplace focused on the pharmaceutical industry in the United States. It operates through Trxade, Inc.; Community Specialty Pharmacy, LLC; Integra Pharma, LLC; and Other segments. The company operates a web based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories, and services. Its principal products and services include Trxade.com, a web-based pharmaceutical marketplace; InventoryRx.com, a web-based pharmaceutical exchange platform; Pharmabayonline that provides proprietary pharmaceutical data analytics and governmental reimbursement benchmarks analysis to the United States-based independent pharmacies and pharmaceutical databases; and RxGuru, an application, which offers product information. The company also operates a retail specialty pharmacy. In addition, it operates Delivmeds.com, a consumer-based app to provide delivery of pharmaceutical products; Trxademso.com to assist independent retail pharmacies on pricing, distribution, and logistics; and Bonum+, a B2B platform to purchase COVID-19 risk assessment and personal protective equipment tools. Trxade Group, Inc. is based in Land O'Lakes, Florida.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.